Identification Of New Pathway Could Control Response Of Neuroblastoma Tumors To Treatment

Children with aggressive neuroblastoma have low survival rates due to frequent recurrences and treatment resistance. A better understanding of the ways neuroblastoma tumors develop resistance to therapy will provide improved treatment options for these children. Growth factor receptors are proteins on tumor cells that can promote tumor cell survival, growth and spread, and the amounts of growth factor receptors found on neuroblastoma tumor cells can be associated with chemotherapy resistance. However, the ways in which tumor cells control the levels and activity of growth factor receptors are not understood.

Some tumor cells have been shown to control the levels of growth factor receptors through recycling of “used” receptors back to the tumor cell surface. Recently a collaborative group including investigators from Texas Children’s Hospital demonstrated that UBE4B, a protein whose gene is often lost in neuroblastoma tumors, interacts with other proteins responsible for control of growth factor receptor recycling within tumor cells, suggesting a connection between growth factor receptor recycling and neuroblastoma tumor response to treatment.

The investigators demonstrated that the amount of the UBE4B gene that is expressed in neuroblastoma tumors directly correlates with the chances of patients surviving, with low gene expression associated with lower chances of survival. The investigators also demonstrated that UBE4B levels are associated with the levels of the epidermal growth factor receptor (EGFR), and that the function of UBE4B could affect the responses of neuroblastoma tumors to EGFR inhibitory drugs (Zage and Bean 2012; Zage et al 2013).

The exciting results of this and other research projects at Texas Children’s Hospital will help identify better treatments and identify new targets for future drug development for children with neuroblastoma. New treatment strategies are currently undergoing testing at Texas Children’s Hospital and future research by the scientists in the neuroblastoma program at Texas Children’s Hospital will continue to explore new pathways, new targets, and new treatments in order to provide the most appropriate and most effective therapy for each and every child with neuroblastoma.

Zage P.E.*, N. Sirisaengtaksin*, Y. Liu, M. Gireud, B.S. Brown, S. Palla, K.N. Richards, D.P.M. Hughes, and A.J. Bean. UBE4B Levels Are Correlated with Clinical Outcomes in Neuroblastoma Patients and with Altered Neuroblastoma Cell Proliferation and Sensitivity to EGFR Inhibitors. Cancer. In Press. PMID: 22990745

Zage, P.E. and A.J. Bean. 2012. Growth Factor Receptor Trafficking as a Potential Therapeutic Target in Pediatric Cancer. Frontiers in Biology. 7 (1): 1-13.


About Dr. Peter Zage, Pediatric Oncologist

I am a pediatric oncologist on the solid tumor and developmental therapeutics teams in Texas Children's Cancer and Hematology Centers, specializing in the treatment of children with neuroblastoma.

At Texas Children's Hematology and Cancer Centers, we are developing a comprehensive program for the treatment of children with neuroblastoma, including special treatment programs for children and adults with high-risk neuroblastoma, recurrent or refractory neuroblastoma, and opscolonus-myocolnus syndrome, incorporating chemotherapy, novel biologically targeted agents, and immunotherapy. In my laboratory, we are interested in evaluating the efficacy of novel therapies against neuroblastoma tumor cells and in understanding the underlying causes of neuroblastoma growth and spread that could be used as targets for the development of new treatments.

Posted in Cancer and Hematology, Research

2 Responses to Identification Of New Pathway Could Control Response Of Neuroblastoma Tumors To Treatment

  1. Pingback: Hope for the future – The Summer Allen Appeal – Help Me Beat Neuroblastoma Cancer!

  2. Pingback: This Week in Neuroblastoma – 1/21/13 | Because of Ezra

Leave a Reply

Your email address will not be published. The * fields are required. Links are not allowed.